The independent medical news service
Lung cancer
30-05-2022 | Oncology | News | Article
PFS gain with aumolertinib in EGFR-mutant advanced NSCLC
First-line treatment with the third-generation EGFR–tyrosine kinase inhibitor aumolertinib significantly improves progression-free survival relative to gefitinib in people with advanced non-small-cell lung cancer and sensitizing EGFR mutations, indicate Chinese trial data.
20-05-2022 | Oncology | News | Article
QoL and OS benefits linked in cancer treatment trials
Around a quarter of phase 3 randomized controlled trials for advanced cancer show an improvement in global quality of life and this is significantly linked to improvements in overall survival, Canadian researchers say.
04-05-2022 | Oncology | News | Article
Online PRO monitoring improves management of irAEs in people with cancer
Electronic patient-reported outcomes to monitor immune-related adverse events during immunotherapy for cancer is associated with a reduction in the incidence of serious adverse events, emergency department visits, and treatment discontinuations, and a better quality of life, research suggests.
27-04-2022 | Oncology | News | Article
Neurologic AE risk lower with ICIs vs chemotherapy
The risk for neurologic adverse events is significantly lower with immune checkpoint inhibitors than with other cancer treatments, particularly chemotherapy, suggest results of a systematic review and meta-analysis.